KEVZARA DIN 02472988
Status: Marketed
Holder: SANOFI-AVENTIS CANADA INC
Health Canada record
| Active ingredient(s) | SARILUMAB 200 MG |
|---|
| Dosage form | Solution |
|---|
| Route | Subcutaneous |
|---|
| Schedule | SCHEDULE D; PRESCRIPTION |
|---|
| Class | Human |
|---|
| ATC | L04AC14 SARILUMAB |
|---|
| Original market date | 21-Jun-2018 |
|---|
| Current status date | 21-Jun-2018 |
|---|
| Source | Health Canada DPD |
|---|
Establishment licence of the holder
sanofi-aventis Canada Inc. — licence 101470, currently licensed, last inspection rating C (2026-02-17).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing SARILUMAB
| DIN | Product | Company | Form | Strength | Status |
|---|
| 02460548 | KEVZARA | SANOFI-AVENTIS CANADA INC | Solution | SARILUMAB 200 MG | Marketed |
| 02472961 | KEVZARA | SANOFI-AVENTIS CANADA INC | Solution | SARILUMAB 150 MG | Marketed |
| 02460521 | KEVZARA | SANOFI-AVENTIS CANADA INC | Solution | SARILUMAB 150 MG | Cancelled Post Market |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|
| 20483 | 2018-02-14 | Supplement to a New Drug Submission (SNDS) | ADDITION OF A NEW PRESENTATION |
Request a quote for KEVZARA
How to read a Canadian DIN record